• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Equillium Inc.

    4/15/26 9:05:02 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EQ alert in real time by email
    DEFA14A 1 eq-defa14a-2026.htm DEFA14A DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under § 240.14a-12

     

    EQUILLIUM, INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

    ☐

    Fee paid previously with preliminary materials

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     


     

     

     

    img256154446_0.jpg

    equillium C/O TABULATOR, P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! Equillium, Inc. Annual Meeting of Stockholders Thursday, May 28, 2026 1:00 PM, Pacific Time Annual Meeting to be held virtually via the internet - please visit www.proxydocs.com/EQ for more details You must register to attend the meeting online and/or participate at www.proxydocs.com/EQ. For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/EQ To vote your proxy while visiting this site, you will need the control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet or by mail. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 12, 2025. SEE REVERSE FOR FULL AGENDA Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On May 28, 2026 For Stockholders of record as of April 1, 2026 To order paper materials, use one of the following methods. Internet: www.investorelections.com/EQ Call: 1-866-648-8133 Email: [email protected] * If requesting material by e-mail, please send a blank e-mail with the control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the control number located in the box above available when you access the website and follow the instructions. Copyright © 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved

     


     

     

     

    img256154446_1.jpg

    equillium Equillium, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR both the nominees for director listed below and FOR Proposals 2, 3 and 4. PROPOSAL 1. 1. To elect the Board's two nominees for Class II director named as nominees in the Proxy Statement to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal; 1.01 Charles McDermott 1.02 Bruce D. Steel 2. To approve an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our common stock at a ratio in the range of 1-for-2 to 1-for-20, inclusive, with such ratio to be determined in the discretion of our Board of Directors and with such reverse stock split to be effected at such time and date, if at all, as determined by our Board of Directors in its sole discretion; 3. To ratify the appointment by the Audit Committee of the Board of Crowe LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026; 4. To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 200,000,000 to 400,000,000 shares; and 5. To conduct any other business properly brought before the Annual Meeting.

     


    Get the next $EQ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EQ

    DatePrice TargetRatingAnalyst
    4/14/2026$6.00Strong Buy
    Raymond James
    4/7/2026$10.00Overweight
    Cantor Fitzgerald
    3/13/2026$12.00Buy
    Roth Capital
    2/25/2026$5.00Buy
    Stifel
    3/28/2025$3.00 → $1.00Outperform → Market Perform
    Leerink Partners
    1/5/2022$18.00 → $14.00Outperform
    SVB Leerink
    10/29/2021$12.00Buy
    Stifel
    9/15/2021$14.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $EQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Equillium with a new price target

    Raymond James initiated coverage of Equillium with a rating of Strong Buy and set a new price target of $6.00

    4/14/26 8:20:53 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Equillium with a new price target

    Cantor Fitzgerald initiated coverage of Equillium with a rating of Overweight and set a new price target of $10.00

    4/7/26 8:44:06 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Equillium with a new price target

    Roth Capital initiated coverage of Equillium with a rating of Buy and set a new price target of $12.00

    3/13/26 8:47:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    SEC Filings

    View All

    SEC Form DEFA14A filed by Equillium Inc.

    DEFA14A - Equillium, Inc. (0001746466) (Filer)

    4/15/26 9:05:02 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Equillium Inc.

    DEF 14A - Equillium, Inc. (0001746466) (Filer)

    4/15/26 9:00:19 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Equillium Inc.

    S-3 - Equillium, Inc. (0001746466) (Filer)

    4/7/26 5:13:14 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sr. Vice President and COO Zedelmayer Christine exercised 120,312 shares at a strike of $0.79 and sold $300,816 worth of shares (120,312 units at $2.50) (SEC Form 4)

    4 - Equillium, Inc. (0001746466) (Issuer)

    3/16/26 6:53:35 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Sr. Vice President and COO Zedelmayer Christine exercised 185,937 shares at a strike of $0.76 and sold $328,104 worth of shares (185,937 units at $1.76) (SEC Form 4)

    4/A - Equillium, Inc. (0001746466) (Issuer)

    3/11/26 8:25:15 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sr. Vice President and COO Zedelmayer Christine exercised 152,361 shares at a strike of $0.79 and sold $362,438 worth of shares (181,219 units at $2.00), decreasing direct ownership by 32% to 62,586 units (SEC Form 4)

    4 - Equillium, Inc. (0001746466) (Issuer)

    3/11/26 8:11:26 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists

    LA JOLLA, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new EQ504 preclinical data have been accepted for poster presentations at IMMUNOLOGY2026™, the annual meeting of the American Association of Immunologists taking place in Boston, Massachusetts, April 15-19, 2026. "We are excited to share these preclinical findings that support the differentiated profile of EQ504 as a potent AhR modulator, with the potential to influence both immune cell responses and barrier restoration," said Dr. Stephen Connelly, Chief Scientific Officer of Equil

    4/8/26 8:30:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LA JOLLA, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on April 1, 2026, the Compensation Committee of Equillium's Board of Directors granted an inducement award consisting of nonstatutory stock options to purchase a total of 32,000 shares of common stock to a new employee under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price per share equal to $2.04, Eq

    4/2/26 4:05:00 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

    Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter Cash and cash equivalents, inclusive of the March 2026 financing, expected to fund operations into 2029 LA JOLLA, Calif, March 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for its fourth quarter and fiscal year ended December 31, 2025. "2025 was a transformative year as we sharpened our strategic focus on EQ504 and strengthened our financia

    3/25/26 4:05:00 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Leadership Updates

    Live Leadership Updates

    View All

    NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

    SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, today announced the appointment of industry veteran and biotech executive Daniel M. Bradbury as Strategic and Metabolic Programs Advisor. "We are thrilled to welcome Dan to NeuraClick," said Dr. Subhi Marwari, Chief Executive Officer. "For an early-stage venture, experienced guidance is essential, and Dan's deep expertise in company building and metabolic therapeutics will be invaluable as we advance our pipeline. He is a phenomenal coach on this journey, helping us navigat

    9/23/25 5:30:46 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium to be included in the Russell Microcap® Index

    Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effective at the open of equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them by total market capitalization. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and va

    6/12/24 8:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

    -Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in

    10/23/23 8:00:00 AM ET
    $CSTL
    $EQ
    $ICPT
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $EQ
    Financials

    Live finance-specific insights

    View All

    Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

    Treatment with itolizumab did not improve complete or overall response rates at Day 29 Itolizumab achieved statistical significance in multiple secondary endpoints demonstrating compelling clinical benefit in longer-term outcomes, including complete response at Day 99, duration of complete response and failure-free survival Breakthrough Therapy designation and meeting requests to discuss potential for Accelerated Approval submitted to FDA, feedback expected during May 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics

    3/27/25 7:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium Maintains Rights to Itolizumab Following Ono Partnership

    Ono Pharmaceutical makes strategic business decision to allow itolizumab option to expire Equillium evaluating accelerating completion of Phase 3 EQUATOR study in aGVHD to Q1 2025 Phase 2 ulcerative colitis study recently completed; topline data expected Q1 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Ono Pharmaceutical Co., Ltd. (Ono) has made the strategic business decision to allow its option to acquire Equillium's rights to itolizumab

    10/31/24 7:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab

    Equillium grants Ono an option to purchase rights to itolizumab Equillium to receive an upfront payment of approximately $26.0M (¥3.5B); eligible to receive up to approximately $138.5M (¥18.7B) in option exercise and milestone payments Ono to fund Equillium's continued research and development of itolizumab during the exercise period Conference call and webcast today at 8:30 a.m. ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, and Ono Pharmaceutical Co., Ltd. ("Ono"), today announced an option and asset purchase agreement through which Ono gains the exclusive option to

    12/6/22 7:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Equillium Inc.

    SC 13G/A - Equillium, Inc. (0001746466) (Subject)

    11/14/24 9:50:36 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Equillium Inc.

    SC 13G - Equillium, Inc. (0001746466) (Subject)

    1/19/24 6:03:46 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Equillium Inc. (Amendment)

    SC 13G/A - Equillium, Inc. (0001746466) (Subject)

    3/3/23 9:27:36 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care